Ocugen Dirección

Dirección controles de criterios 2/4

El CEO de Ocugen's es Shankar Musunuri , nombrado en Sep 2019, tiene una permanencia de 4.42 años. compensación anual total es $7.66M, compuesta por 9.3% salario y 90.7% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.8% de las acciones de la empresa, por valor de €1.88M. La antigüedad media del equipo directivo y de la junta directiva es de 1.4 años y 4.3 años, respectivamente.

Información clave

Shankar Musunuri

Chief Executive Officer (CEO)

US$7.7m

Compensación total

Porcentaje del salario del CEO	9.3%
Permanencia del CEO	4.4yrs
Participación del CEO	0.8%
Permanencia media de la dirección	1.4yrs
Promedio de permanencia en la Junta Directiva	4.3yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Shankar Musunuri en comparación con los beneficios de Ocugen?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2023	n/a	n/a	-US$76m
Jun 30 2023	n/a	n/a	-US$83m
Mar 31 2023	n/a	n/a	-US$80m
Dec 31 2022	US$8m	US$715k	-US$81m
Sep 30 2022	n/a	n/a	-US$74m
Jun 30 2022	n/a	n/a	-US$63m
Mar 31 2022	n/a	n/a	-US$69m
Dec 31 2021	US$8m	US$541k	-US$58m
Sep 30 2021	n/a	n/a	-US$48m
Jun 30 2021	n/a	n/a	-US$47m
Mar 31 2021	n/a	n/a	-US$38m
Dec 31 2020	US$2m	US$500k	-US$34m
Jun 30 2020	n/a	n/a	-US$30m
Mar 31 2020	n/a	n/a	-US$18m
Dec 31 2019	US$572k	US$420k	-US$20m
Sep 30 2019	n/a	n/a	-US$39m
Jun 30 2019	n/a	n/a	-US$18m
Mar 31 2019	n/a	n/a	-US$19m
Dec 31 2018	US$431k	US$420k	-US$18m

Compensación vs. Mercado: La compensación total de Shankar($USD7.66M) está por encima de la media de empresas de tamaño similar en el mercado BG ($USD586.25K).

Compensación vs. Ingresos: La compensación de Shankar ha sido consistente con los resultados de la empresa en el último año.

CEO

Shankar Musunuri (59 yo)

4.4yrs

Permanencia

US$7,662,810

Compensación

Dr. Shankar Musunuri, Ph D., MBA, is the Co-Founder of Ocugen, Inc. and has been its Chairman and Chief Executive Officer and Director since September 27, 2019. He served as Interim Principal Financial Off...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Shankar Musunuri	Co-Founder	4.4yrs	US$7.66m	0.80% $ 1.9m
Uday Kompella	Co-founder & Independent Director	no data	US$341.82k	0.27% $ 643.6k
Michael Breininger	Interim Chief Accounting Officer & Principal Financial Officer and Corporate Controller	less than a year	sin datos	sin datos
Arun Upadhyay	Chief Scientific Officer and Head of Research & Development	1.4yrs	sin datos	0.041% $ 95.4k
John Kouch	General Counsel	no data	sin datos	sin datos
Tiffany Hamilton	Head of Corporate Communications	no data	sin datos	sin datos
Michael Shine	Senior Vice President of Commercial	2.7yrs	sin datos	sin datos
Jyothy Pillai	Head of Regulatory & Quality	less than a year	sin datos	sin datos

1.4yrs

Permanencia media

48.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 2H51 no se considera experimentado ( 1.4 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Shankar Musunuri	Co-Founder	4.4yrs	US$7.66m	0.80% $ 1.9m
Uday Kompella	Co-founder & Independent Director	4.4yrs	US$341.82k	0.27% $ 643.6k
Prabhavathi Fernandes	Independent Director	3.8yrs	US$357.60k	0% $ 0
Carl Regillo	Member of Retina Scientific Advisory Board	4.3yrs	sin datos	sin datos
Ramesh Kumar	Independent Director	4.4yrs	US$347.28k	0% $ 0
David Boyer	Member of Retina Scientific Advisory Board	no data	sin datos	sin datos
Bruce Forrest	Vaccine Scientific Advisory Board Member	3.2yrs	sin datos	sin datos
Junge Zhang	Independent Director	4.4yrs	US$335.56k	0.45% $ 1.1m
Geeta Lalwani	Member of Retina Scientific Advisory Board	no data	sin datos	sin datos
Kirsten Castillo	Independent Director	3.8yrs	US$348.18k	0.019% $ 45.6k
Satishchandran Chandrasekhar	Vaccine Scientific Advisory Board Member	3.2yrs	sin datos	sin datos
Mark Pennesi	Member of Retina Scientific Advisory Board	4.3yrs	sin datos	sin datos

4.3yrs

Permanencia media

59yo

Promedio de edad

Junta con experiencia: La junta directiva de 2H51 se considera experimentada (4.3 años de antigüedad promedio).

Ocugen Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Ocugen, Inc. Appoints Huma Qamar as Chief Medical Officer

Ocugen, Inc. Announces Bob Smith Joins Business Advisory Board

Ocugen, Inc. Appoints Connie Collingsworth to the Business Advisory Board

Ocugen, Inc. Announces Executive Changes

Ocugen, Inc. Announces Business Advisory Board

Ocugen, Inc. Appoints Quan A. Vu as Chief Business Officer

Recent updates

Ocugen, Inc. Announces Ocu400 Modifier Gene Therapy Phase 1/2 Data Presentation At Retinal Cell and Gene Therapy Innovation Summit 2024

Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410 --A Modifier Gene Therapy

Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of Ocugen, Inc

Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial

Ocugen, Inc. Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for Ocu410--A Modifier Gene Therapy-- in Phase 1/2 Armada Study for Geographic Atrophy

Ocugen Provides Business Update

Ocugen, Inc. to Report Q4, 2023 Results on Apr 02, 2024

Ocugen, Inc. Appoints Huma Qamar as Chief Medical Officer

Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410

Ocugen, Inc. Announces Dosing Completion of Subjects with Stargardt in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST

Ocugen, Inc. Announces Bob Smith Joins Business Advisory Board

Ocugen, Inc. Gains FDA Alignment on Key Aspects of OCU400 —Modifier Gene Therapy—Pivotal Phase 3 Study Design

Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410—Modifier Gene Therapy—For Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST --Modifier Gene Therapy-- for Stargardt Disease

Ocugen, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Ocugen, Inc. Announces Ocugen Mucosal Vaccine Candidate OCU500 Selected by NIH NIAID Project NextGen for Inclusion in Clinical Trials

Ocugen, Inc. Appoints Connie Collingsworth to the Business Advisory Board

Ocugen, Inc. Announces Executive Changes

Ocugen, Inc. Announces Positive Clinical Study Update from the Phase 1/2 Trial of Ocu400, A Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa and Leber Congenital Amaurosis

Ocugen, Inc. to Report Q2, 2023 Results on Aug 21, 2023

Ocugen, Inc. announced delayed 10-Q filing

Ocugen, Inc. Announces Business Advisory Board

Ocugen, Inc. has completed a Follow-on Equity Offering in the amount of $15 million.

Ocugen, Inc. has completed a Follow-on Equity Offering.

No longer forecast to breakeven

Ocugen, Inc. to Report Q4, 2022 Results on Feb 28, 2023

Ocugen, Inc. Appoints Quan A. Vu as Chief Business Officer

Ocugen, Inc. Announces Positive Top-Line Data for COVID-19 Vaccine Candidate COVAXIN™ (BBV152) in Phase 2/3 Immuno-Bridging and Broadening Study: Both Co-Primary Endpoints Met

Forecast to breakeven in 2025

Ocugen, Inc Announces Update on OCU400 Phase 1/2 Clinical Trial Targeting Retinitis Pigmentosa and Leber Congenital Amaurosis

High number of new directors

Ocugen, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Ocugen Announces Completion of Dosing in OCU400 Phase 1/2 Cohort 2

Ocugen, Inc. Announces Publication of Comprehensive Review of BBV152 in Frontiers in Immunology

Ocugen, Inc. Announces Board Changes

No longer forecast to breakeven

Ocugen, Inc. to Report Q2, 2022 Results on Aug 05, 2022

Ocugen, Inc. Announces Publication of Positive Results of Covid-19 Vaccine Trial for Children 2 18 in the Lancet Infectious Diseases

Ocugen, Inc. Announces New Cell Therapy Program Following FDA Regenerative Medicine Advanced Therapy (RMAT) Recognition

Ocugen, Inc. Announces New Cell Therapy Program Following FDA Regenerative Medicine Advanced Therapy (RMAT) Recognition

Ocugen Announces FDA Removes Clinical Hold on Phase 2/3 Clinical Trial for Covaxin (Bbv152)

Forecast breakeven date pushed back to 2023

Ocugen, Inc. to Report Q1, 2022 Results on May 06, 2022

High number of new and inexperienced directors

Ocugen, Inc. Announces Positive DSMB Recommendation for OCU400-101 Clinical Trial

Ocugen, Inc. Provides Update on its Phase 2/3 Study of COVAXIN™ (BBV152)

Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial for Gene Therapy Candidate OCU400 to Treat Inherited Retinal Degeneration

Ocugen, Inc. Announces Resignation of Sanjay S. Subramanian as Chief Financial Officer

Ocugen, Inc. Provides Update on its COVAXIN™ Pediatric (2-18) Emergency Use Authorization Request

Forecast breakeven date pushed back to 2023

Ocugen, Inc. has completed a Follow-on Equity Offering in the amount of $53.5 million.

Ocugen, Inc. has completed a Follow-on Equity Offering in the amount of $53.5 million.

Ocugen, Inc. Announces U.S. FDA Lifts Clinical Hold on the Submission of its Investigational New Drug Application for Its COVID-19 Vaccine Candidate COVAXIN™ (BBV152)

Ocugen, Inc. (NasdaqCM:OCGN) signed a non-binding letter of intent to acquire a manufacturing site in Belleville, Ontario from Liminal BioSciences Inc. (DB:PJ2N).

Ocugen, Inc. and Bharat Biotech Announce Results from a Study Conducted at Emory University

Ocugen, Inc. Announces COVAXIN (BBV152) Booster Dose Study Demonstrates Robust Immune Responses and Long-Term Safety

Ocugen Partner, Bharat Biotech, Announces Positive Immunogenicity and Safety Data From COVAXIN (BBV152), COVID-19 Candidate Vaccine

Ocugen, Inc. announces New Data Suggest COVAXIN™ (BBV152) Vaccine Candidate Generates Robust Immune Memory to COVID-19 and Variants of Concern for At Least Six Months After Vaccination

High number of new and inexperienced directors

Ocugen, Inc. Announces U.S. Fda Acceptance of Investigational New Drug Application to Initiate A Phase 1/2 Clinical Trial for Gene Therapy Candidate Ocu400 to Treat Inherited Retinal Degeneration

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media